Abstract: The present specification discloses tetrahydroindolone derivatives or analogues and methods for treating cognitive/attention deficit disorders using such tetrahydroindolone derivatives and analogues.
Type:
Grant
Filed:
September 27, 2011
Date of Patent:
February 19, 2013
Assignee:
Spectrum Pharmaceuticals, Inc.
Inventors:
Alvin J. Glasky, David B. Fick, David R. Helton
Abstract: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).
Abstract: Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
Type:
Application
Filed:
June 11, 2012
Publication date:
October 4, 2012
Applicant:
Spectrum Pharmaceuticals, Inc.
Inventors:
Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen
Abstract: The invention relates to methods of treatment or prophylaxis of physiological and/or pathological conditions with at least one LHRH antagonist, in particular at least one peptidomimetic LHRH antagonist such that the at least one LHRH antagonist is administered in a dose, which does not cause chemical (hormonal) castration.
Abstract: The present specification discloses tetrahydroindolone derivatives or analogues and methods for treating cognitive/attention deficit disorders using such tetrahydroindolone derivatives and analogues.
Type:
Application
Filed:
September 27, 2011
Publication date:
March 22, 2012
Applicant:
SPECTRUM PHARMACEUTICALS, INC.
Inventors:
Alvin J. Glasky, David B. Fick, David Helton
Abstract: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.
Type:
Application
Filed:
September 9, 2011
Publication date:
December 29, 2011
Applicant:
SPECTRUM PHARMACEUTICALS, INC.
Inventors:
Rudi E. Moerck, Timothy Malcome Spitler, Edward A. Schauer, Jan Prochazka
Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.
Type:
Application
Filed:
August 29, 2011
Publication date:
December 29, 2011
Applicants:
The Board of Trustees of the University of Illinois, Spectrum Pharmaceuticals, Inc.
Abstract: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).
Type:
Application
Filed:
August 29, 2011
Publication date:
December 22, 2011
Applicants:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, SPECTRUM PHARMACEUTICALS, INC.
Abstract: Methods for treating cognitive/attention deficit disorders in general using tetrahydroindolone derivatives and analogues, particularly tetrahydroindolone derivatives or analogues in which the tetrahydroindolone derivative or analogue is covalently linked to another moiety to form a bifunctional conjugate are disclosed. More specifically, methods and compositions for treating attention deficit disorder and attention deficit hyperactivity disorders in adults and children as well as mild cognitive impairment and dementia are provided.
Type:
Grant
Filed:
March 30, 2009
Date of Patent:
November 22, 2011
Assignee:
Spectrum Pharmaceuticals Inc.
Inventors:
Alvin J. Glasky, David B. Fick, David R. Helton
Abstract: The present invention is a method of producing a lanthanum carbonate hydroxide or lanthanum oxycarbonate which has improved properties. The method involves the use of a water soluble lanthanum and a water soluble non-alkali metal carbonate or bicarbonate. The resulting material can be used as a phosphate binder individually or for treating patients with hyperphosphatemia.
Type:
Application
Filed:
May 12, 2011
Publication date:
November 17, 2011
Applicant:
SPECTRUM PHARMACEUTICALS, INC.
Inventors:
Ashok Yeshwant Gore, Milind Dixit, Ravichandran Mahalingam, Edward A. Schauer, Matthew Stewart, Rajendra Tandale
Abstract: Formulations containing stable forms of elsamitrucin salts are provided. These formulations are useful for treating neoplastic diseases and conditions.
Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.
Type:
Grant
Filed:
February 20, 2009
Date of Patent:
October 4, 2011
Assignees:
Spectrum Pharmaceuticals, Inc., Board of Trustees University of Illinois
Abstract: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).
Type:
Grant
Filed:
April 10, 2008
Date of Patent:
September 27, 2011
Assignees:
Spectrum Pharmaceuticals, Inc., Board of Trustees University of Illinois
Abstract: Methods for treating bladder cancer comprising intravesicular administration of a stabilized pharmaceutical formulation comprising 5-(1-aziridinyl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methyl-1H-indole-4,7-dione (EO9). More specifically, the stabilized pharmaceutical formulation is instilled in the bladder for a time sufficient to treat the cancer.
Type:
Grant
Filed:
March 21, 2008
Date of Patent:
July 12, 2011
Assignee:
Spectrum Pharmaceuticals, Inc.
Inventors:
Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen
Abstract: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.
Type:
Application
Filed:
February 1, 2011
Publication date:
May 26, 2011
Applicant:
SPECTRUM PHARMACEUTICALS, INC.
Inventors:
Rudi E. Moerck, Timothy Malcome Spitler, Edward A. Schauer, Jan Prochazka
Abstract: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.
Type:
Application
Filed:
June 14, 2010
Publication date:
November 4, 2010
Applicant:
SPECTRUM PHARMACEUTICALS, INC.
Inventors:
Rudi E. Moerck, Timothy Malcome Spitler, Edward A. Schauer, Jan Prochazka
Abstract: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.
Type:
Application
Filed:
December 21, 2009
Publication date:
August 5, 2010
Applicant:
SPECTRUM PHARMACEUTICALS, INC.
Inventors:
Rudi E. Moerck, Timothy Malcome Spitler, Edward A. Schauer, Jan Prochazka
Abstract: The present invention is generally directed to compositions and formulations that can be used for the treatment of diseases such as End Stage Renal Disease (“ESRD”) and Chronic Renal Insufficiency (“CRI”). Specifically, it is directed to lanthanum-based compounds that bind phosphate and that can be formulated to provide for a reduced pill burden relative to other phosphate binders. In a formulation aspect of the present invention, a formulation is provided the includes a lanthanum-based, phosphate binder. The formulation is typically characterized in that in may be swallowed without chewing. Formulations of the present invention, along with a lanthanum-based compound, may optionally include the following: mass diluting agents; binders; coatings; compression/encapsulation aids; disintegrants; lubricants; plasticizers; slip/anti-electrostatic agents; powder lubricants; and, sweeteners. Where the formulation is in the form of a tablet, it typically has a volume between 0.3 cm3 and 1.2 cm3, preferably between 0.
Abstract: Methods for treating cognitive/attention deficit disorders in general using tetrahydroindolone derivatives and analogues, particularly tetrahydroindolone derivatives or analogues in which the tetrahydroindolone derivative or analogue is covalently linked to another moiety to form a bifunctional conjugate are disclosed. More specifically, methods and compositions for treating attention deficit disorder and attention deficit hyperactivity disorders in adults and children as well as mild cognitive impairment and dementia are provided.
Type:
Application
Filed:
March 30, 2009
Publication date:
July 30, 2009
Applicant:
Spectrum Pharmaceuticals, Inc.
Inventors:
Alvin J. Glasky, David B. Fick, David Helton